…the very low number of scripts being reported are for 92% of the HCV population. What is not being reported is the scripts for 8% of the population.
That’s not an especially helpful metric for investors. Rather, what investors are trying to estimate is ABBV’s market share of patients currently being treated.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”